Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harvey Quon

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Anticancer Research|October 4, 2011
Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapyHarvey Quon, Bryan Brunet, Abraham Alexander, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancerHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicityHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 10, 2009
A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancerKurian Jones Joseph, Alasdair Syme, Cormac Small, et al.
Radiation Oncology (London, England)|November 5, 2021
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trialJulian O Kim, Megan O McDonald, Aldrich Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
International Journal of Radiation Oncology, Biology, Physics|July 30, 2022
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled TrialNawaid Usmani, Sunita Ghosh, Karan P Sanghera, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Anticancer Research|October 4, 2011
Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapyHarvey Quon, Bryan Brunet, Abraham Alexander, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2011
Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancerHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|January 18, 2011
Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicityHarvey Quon, Patrick C F Cheung, D Andrew Loblaw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 10, 2009
A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancerKurian Jones Joseph, Alasdair Syme, Cormac Small, et al.
Radiation Oncology (London, England)|November 5, 2021
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trialJulian O Kim, Megan O McDonald, Aldrich Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
International Journal of Radiation Oncology, Biology, Physics|July 30, 2022
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled TrialNawaid Usmani, Sunita Ghosh, Karan P Sanghera, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
Pageof 5